Danaher Corporation's Stock Analysis

Danaher to Acquire Masimo for $180 Per Share

Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation for $180 per share in cash, totaling approximately $9.9 billion including debt. The merger will see Masimo continue as a wholly owned subsidiary of Danaher and is expected to close in the second half of 2026, pending regulatory approvals and shareholder consent. Danaher anticipates that the acquisition will enhance its diagnostics segment and is expected to yield significant annual cost and revenue synergies over the next five years.

Upon completion, Masimo is projected to contribute positively to Danaher’s earnings, with an estimated adjusted diluted net earnings increase of $0.15 to $0.20 in the first full year and around $0.70 by the fifth year post-acquisition. Danaher expects Masimo to achieve more than $530 million in EBITDA by 2027, alongside anticipated annual synergies of over $175 million. The acquisition is expected to strengthen Danaher's position in the diagnostics market, particularly in acute care settings.

Feb 17, 2026 08:08:12

Danaher Board Member Jessica Mega Announces Retirement

Jessica L. Mega has informed Danaher Corporation's Board of Directors that she will retire from her position effective February 5, 2026. Her decision to step down is attributed to commitments related to her other professional obligations and is not due to any disagreements with the company regarding its operations or policies.

This change in the Board's composition may be of interest to investors as it reflects potential shifts in governance and oversight at Danaher. The company has confirmed that Dr. Mega's retirement is amicable, ensuring continuity in its leadership and strategic direction.

Feb 10, 2026 16:22:59

Danaher Reports Financial Results for 2025 Fiscal Year

Danaher Corporation reported its financial results for the fourth quarter and full year of 2025, highlighting net earnings of $1.2 billion for Q4, or $1.66 per diluted share, and $3.6 billion for the full year, equating to $5.03 per diluted share. Revenue for Q4 increased by 4.5% to $6.8 billion, while full-year revenue rose by 3.0% to $24.6 billion. The company generated $2.1 billion in operating cash flow in Q4 and $6.4 billion for the full year, with non-GAAP free cash flow reported at $1.8 billion and $5.3 billion, respectively.

In 2025, Danaher launched several innovative products aimed at enhancing its position in life sciences and diagnostics, including advancements in bioprocessing and diagnostics technologies. For 2026, the company anticipates a low-single digit increase in non-GAAP core revenue for Q1 and a projected growth of 3% to 6% for the full year. Additionally, Danaher has initiated guidance for adjusted diluted net earnings per share in the range of $8.35 to $8.50.

Jan 27, 2026 17:37:52

Danaher Projects Revenue Growth and Strong Earnings for 2025

Danaher Corporation announced estimated financial performance for the fourth quarter of 2025, projecting mid-single digit revenue growth year-over-year and non-GAAP core revenue growth towards the high end of previously announced guidance. The anticipated adjusted diluted net earnings per share for the full year 2025 is expected to be between $7.70 and $7.80, reflecting a solid finish to the year, particularly in the Bioprocessing, Life Sciences, and Diagnostics segments.

The company emphasized its strong positioning in key markets, with expected core revenue growth of 3% to 6% for 2026. Danaher highlighted its differentiated portfolio and the strength of its business model, which includes a significant portion of recurring revenue. The upcoming quarterly earnings call is scheduled for January 28, 2026, where further details on financial performance and strategic initiatives will be discussed.

Jan 12, 2026 09:07:26

Danaher Board Member John T. Schwieters to Retire in 2026

John T. Schwieters has informed Danaher’s Board of Directors that he will not seek reelection at the 2026 annual meeting and will retire from the Board at that time. His decision is not due to any disagreements regarding the Company’s operations or policies.

Following Mr. Schwieters’ retirement, the size of Danaher’s Board will decrease from thirteen members to twelve. This change will take effect at the 2026 Annual Meeting.

Nov 06, 2025 16:41:45

Danaher Reports Third Quarter 2025 Financial Results and Guidance

Danaher Corporation announced its financial results for the third quarter ending September 26, 2025, reporting net earnings of $908 million, or $1.27 per diluted share, with non-GAAP adjusted earnings at $1.89 per share. Revenues increased by 4.5% year-over-year to $6.1 billion, while non-GAAP core revenue rose by 3.0%. The company generated $1.7 billion in operating cash flow and $1.4 billion in non-GAAP free cash flow, reflecting strong performance driven by its bioprocessing business and respiratory revenue at Cepheid.

For the full year 2025, Danaher is maintaining its adjusted diluted net earnings guidance in the range of $7.70 to $7.80 per share, with an expectation of low-single-digit growth in non-GAAP core revenue. The company has not provided reconciliations for certain non-GAAP measures due to the unpredictability of additional elements that could affect results. Investors can access further details through the company's investor conference call and related webcasts.

Oct 20, 2025 17:39:47

Danaher Approves New Share Repurchase Program for 35 Million Shares

Danaher Corporation's Board of Directors has amended the Company’s By-laws to update the procedures for shareholders to propose business at meetings, including director nominations. These changes also include routine updates and revisions to the By-laws.

On the same date, the Board approved a new share repurchase program allowing the Company to buy back up to 35 million shares of its common stock. This program can be executed through various methods such as open market purchases and has no expiration date, continuing until further notice. The management will determine the timing and amount of repurchases based on market conditions.

Sep 10, 2025 07:24:19

Danaher General Counsel to Transition Role Before Retirement

Brian W. Ellis, Senior Vice President and General Counsel of Danaher Corporation, has announced his intention to step down from his role as General Counsel effective August 25, 2025. He will continue to serve as Senior Vice President until his retirement on February 28, 2026.

This transition in leadership may impact the company's legal and operational strategies during the upcoming months as Danaher prepares for Ellis's eventual retirement. Investors may want to monitor any changes in the company's governance structure or legal affairs as a result of this announcement.

Jul 31, 2025 16:31:51

Danaher Announces CFO Transition and Compensation Changes

Matthew M. McGrew, the current Chief Financial Officer of Danaher Corporation, will step down from his role effective February 28, 2026, transitioning to continue as an Executive Vice President. Matthew E. Gugino, currently the Group CFO for the Life Sciences Innovations Group, will succeed him. Gugino's compensation will increase to an annual base salary of $825,000, with a target bonus percentage of 115% and a target equity compensation value of $4,200,000 for 2026, reflecting his new role. McGrew's base salary will also be adjusted to $700,000 with a target bonus of 125% upon his transition.

The company has established agreements to protect proprietary interests and ensure non-competition from Gugino during and after his employment. McGrew has been with Danaher for over 20 years and played a significant role in the company's growth, including major acquisitions and navigating challenges during the pandemic. The transition is expected to occur smoothly, with McGrew remaining to support the company during this period.

Jul 24, 2025 16:50:27

Danaher Reports Second Quarter 2025 Financial Results

Danaher Corporation announced its financial results for the quarter ending June 27, 2025, reporting net earnings of $555 million, equivalent to $0.77 per diluted share. Revenue increased by 3.5% year-over-year to $5.9 billion, with non-GAAP core revenue growth of 1.5%. Operating cash flow was reported at $1.3 billion, and non-GAAP free cash flow reached $1.1 billion. The company's CEO highlighted the robust growth in the Bioprocessing sector and effective cost management as key contributors to exceeding quarterly expectations.

For the upcoming quarters, Danaher anticipates low-single-digit growth in non-GAAP core revenue for the third quarter and maintains a full-year growth expectation of approximately 3%. The company has also raised its guidance for adjusted diluted net earnings per share to a range of $7.70 to $7.80, up from the previous estimate of $7.60 to $7.75. An investor conference call was scheduled to discuss these results and future financial guidance.

Jul 21, 2025 17:47:55